Lv1
48 积分 2025-06-30 加入
Durvalumab plus paclitaxel/carboplatin plus bevacizumab followed by durvalumab,bevacizumab plus olaparib maintenance a- mong patients with newly-diagnosed advanced ovarian cancer without a tumor BRCA1/BRCA2 mutation: updated results from DUO-0/ENGOT-OV46/GOG-3025 trial
1个月前
已完结
Cost-effectiveness of poly-(ADP-ribose) polymerase (PARP)-inhibitors for the maintenance treatment after responding to first- and second-line chemotherapy in advanced ovarian cancer
2个月前
已完结
Expression of Uptake Hydrogenase and Molybdenum Nitrogenase in Rhodobacter capsulatus Is Coregulated by the RegB-RegA Two-Component Regulatory System
2个月前
已完结
PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: A cost-effectiveness analysis
2个月前
已完结
RWD154 Healthcare Resource Utilization (HCRU) and Costs of Poly(ADP-ribose) Polymerase Inhibitors (PARPi) as First-Line Maintenance (1LM) Treatment for Ovarian Cancer (OC)
2个月前
已关闭
Cost-effectiveness analysis of niraparib maintenance therapy in Chinese patients with platinum-sensitive recurrent ovarian cancer
2个月前
已完结
Lenvatinib, sintilimab plus transarterial chemoembolization for advanced stage hepatocellular carcinoma: A phase II study
3个月前
已完结
Fuzuloparib as maintenance therapy among patients with advanced ovarian cancer after a response to first-line platinum-based chemotherapy: Results from a randomized, placebo-controlled, phase III trial
4个月前
已完结
Randomized CLIO/BGOG-ov10 trial of olaparib monotherapy versus physician's choice chemotherapy in relapsed ovarian cancer
6个月前
已关闭
皖公网安备34019202002308
